StockNews.AI
OFIX
StockNews.AI
153 days

Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System

1. Orthofix receives FDA clearance and CE Mark for TrueLok Elevate system. 2. The system aids in treating complex tissue defects and diabetic foot ulcers.

2m saved
Insight
Article

FAQ

Why Very Bullish?

FDA clearance typically boosts stock prices. Historical examples show similar releases led to price surges.

How important is it?

FDA and CE approvals herald expansion potential and revenue growth for OFIX.

Why Long Term?

The approval may significantly enhance market presence over time as adoption increases.

Related Companies

MDTZBHSNN
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT.

Related News